Enamel matrix proteins, including the most abundant amelogenin and lesser amounts of enamelin, ameloblastin, and proteinases, play vital roles in controlling crystal nucleation and growth during enamel formation. The cooperative action between amelogenin and the 32-kDa enamelin is critical to regulating the growth morphology of octacalcium phosphate crystals. Using biophysical methods, we investigated the interaction between the 32-kDa enamelin and recombinant pig amelogenin 148 (rP148) at pH 6.5 in phosphate-buffered saline (PBS). Dynamic light scattering results showed a trend of increasing particle size in the mixture with the addition of enamelin to amelogenin. Upon addition of the 32-kDa enamelin, the shift and intensity decrease in the ellipticity minima of rP148 in the circular dichroism spectra of rP148 illustrated a direct interaction between the 2 proteins. In the fluorescence spectra, the maximum emission of rP148 was blue shifted from 335 to 333 nm in the presence of enamelin as a result of complexation of the 2 proteins. Our results demonstrate that the 32-kDa enamelin has a close association with amelogenin at pH 6.5 in PBS buffer. Our present study provides novel insights into the possible cooperation between enamelin and amelogenin in macromolecular coassembly and in controlling enamel mineral formation

Keywords:
Enamel, 32-kDa enamelin, Amelogenin self-assembly, Circular dichroism, Dynamic light scattering, Fluorescence spectroscopy, Octacalcium phosphate
1.
Bouropoulos, N., J. Moradian-Oldak (2004) Induction of apatite by the cooperative effect of amelogenin and the 32-kDa enamelin. J Dent Res 83: 278–282.
2.
Fan, D., C. Du, Z. Sun, R. Lakshminarayanan, J. Moradian-Oldak (2009) In vitro study on the interaction between the 32 kDa enamelin and amelogenin. J Struct Biol 166: 88–94.
3.
Fan, D., R. Lakshminarayanan, J. Moradian-Oldak (2008) The 32 kDa enamelin undergoes conformational transitions upon calcium binding. J Struct Biol 163: 109–115.
4.
Gibson, C.W., Z.A. Yuan, B. Hall, G. Longenecker, E. Chen, T. Thyagarajan, T. Sreenath, J.T. Wright, S. Decker, R. Piddington, G. Harrison, A.B. Kulkarni (2001) Amelogenin-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem 276: 31871–31875.
5.
Gutierrez, S.J., M. Chaves, D.M. Torres, I. Briceno (2007) Identification of a novel mutation in the enamelin gene in a family with autosomal-dominant amelogenesis imperfecta. Arch Oral Biol 52: 503–506.
6.
Hu, C.C., Y. Hu, C.E. Smith, M.D. McKee, J.T. Wright, Y. Yamakoshi, P. Papagerakis, G.K. Hunter, J.Q. Feng, F. Yamakoshi, J.P. Simmer (2008) Enamel defects and ameloblast-specific expression in Enam knock-out/lacZ knock-in mice. J Biol Chem 283: 10858–10871.
7.
Hu, C.C., Y. Yamakoshi (2003) Enamelin and autosomal-dominant amelogenesis imperfecta. Crit Rev Oral Biol Med 14: 387–398.
8.
Iijima, M., D. Fan, K.M. Bromley, Z. Sun, J. Moradian-Oldak (2010) Tooth enamel proteins enamelin and amelogenin cooperate to regulate the growth morphology of octacacium phosphate crystals. Crystal Growth Des, in press.
9.
Iijima, M., Y. Moriwaki, T. Takagi, J. Moradian-Oldak (2001) Effects of bovine amelogenins on the crystal morphology of octacalcium phosphate in a model system of tooth enamel formation. J Cryst Growth 222: 615–626.
10.
Kida, M., T. Ariga, T. Shirakawa, H. Oguchi, Y. Sakiyama (2002) Autosomal-dominant hypoplastic form of amelogenesis imperfecta caused by an enamelin gene mutation at the exon-intron boundary. J Dent Res 81: 738–742.
11.
Kwak, S.Y., F.B. Wiedemann-Bidlack, E. Beniash, Y. Yamakoshi, J.P. Simmer, A. Litman, H.C. Margolis (2009) Role of 20-kDa amelogenin (P148) phosphorylation in calcium phosphate formation in vitro. J Biol Chem 284: 18972–18979.
12.
Laksminarayanan, R., K.M. Bromley, Y.P. Lei, M.L. Snead, J. Moradian-Oldak (2010) Perturbed amelogenin secondary structure leads to uncontrolled aggregation in amelogenesis imperfecta mutant proteins. J Biol Chem, in press.
13.
Lakshminarayanan, R., D. Fan, C. Du, J. Moradian-Oldak (2007) The role of secondary structure in the entropically driven amelogenin self-assembly. Biophys J 93: 3664–3674.
14.
Margolis, H.C., E. Beniash, C.E. Fowler (2006) Role of Macromolecular Assembly of Enamel Matrix Proteins in Enamel Formation. J Dent Res 85: 775–793.
15.
Moradian-Oldak, J., M. Goldberg (2005) Amelogenin supra-molecular assembly in vitro compared to the architecture of the forming enamel matrix. Cells Tissue Organs 181: 202–218.
16.
Ozdemir, D., P.S. Hart, E. Firatli, G. Aren, O.H. Ryu, T.C. Hart (2005) Phenotype of ENAM mutations is dosage-dependent. J Dent Res 84: 1036–1041.
17.
Ravindranath, R.H., J. Moradian-Oldak, A.G. Fincham (1999) Tyrosyl motif in amelogenins binds N-acetyl-D-glucosamine. J Biol Chem 274: 2464–2471.
18.
Sun, Z., M.M. Ahsan, H. Wang, C. Du, C. Abbott, J. Moradian-Oldak, (2006) Assembly and processing of an engineered amelogenin proteolytic product (rP148). Eur J Oral Sci 114(suppl 1): 59–63 (discussion 93–95, 379–380).
19.
Yang, X., L. Wang, Y. Qin, Z. Sun, Z.J. Henneman, J. Moradian-Oldak, G.H. Nancollas (2010) How amelogenin orchestrates the organization of hierarchical elongated microstructures of apatite. J Phys Chem B 114: 2293–2300.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.